Pharmacodynamics +<unk>  Site pKi Ki (nM) Action 5-HT1A 8.6 2.5 Partial agonist 5-HT1B 8.4 4.0 Antagonist 5-HT2A 10.2 0.06 Antagonist 5-HT2B 9.8 0.16 Antagonist 5-HT2C 10.5 0.03 Antagonist 5-HT5A 8.8 1.6 Antagonist 5-HT6 9.5 0.25 Antagonist 5-HT7 9.9 0.13 Antagonist α1 8.9 1.2 Antagonist α2A 8.9 1.2 Antagonist α2B 9.5 0.32 Antagonist α2C 8.9 1.2 Antagonist D1 8.9 1.4 Antagonist D2 8.9 1.3 Antagonist D3 9.4 0.42 Antagonist D4 9.0 1.1 Antagonist H1 9.0 1.0 Antagonist H2 8.2 6.2 Antagonist mACh 1A (8.6), 5-HT1B (8.4), 5-HT2A (10.2), 5-HT2B (9.8), 5-HT2C (10.5), 5-HT5A (8.8), 5-HT6 (9.5), and 5-HT7 (9.9) receptors, the adrenergic α1 (8.9), α2A (8.9), α2B (9.5), and α2C (8.9) receptors, the dopamine D1 (8.9), D2 (8.9), D3 (9.4), and D4 (9.0) receptors, and the histamine H1 (9.0) and H2 (8.2) receptors. It has much lower affinity (pKi 1A receptors. At all other targets<unk>  is an antagonist. As of November 2010<unk>  is also in clinical trials at UC Irvine to treat stuttering. Even relative to other atypical antipsychotics,<unk>  has unusually high affinity for the 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors, and very high affinity for the α2 and H1 receptors.
Asenapine
Sertraline
Aripiprazole
Mirtazapine
Loxapine
Amoxapine
Perlapine
Trimipramine